» Authors » Nathan G Hatcher

Nathan G Hatcher

Explore the profile of Nathan G Hatcher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 679
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Vandenbosch M, Mutuku S, Mantas M, Patterson N, Hallmark T, Claesen M, et al.
Anal Chem . 2023 Dec; 95(51):18719-18730. PMID: 38079536
Mass spectrometry imaging (MSI) has accelerated our understanding of lipid metabolism and spatial distribution in tissues and cells. However, few MSI studies have approached lipid imaging quantitatively and those that...
2.
Leyns C, Prigent A, Beezhold B, Yao L, Hatcher N, Tao P, et al.
NPJ Parkinsons Dis . 2023 May; 9(1):74. PMID: 37169750
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases characterized by the accumulation of misfolded α-synuclein in the form of Lewy pathology. While most cases are...
3.
Roecker A, Schirripa K, Loughran H, Tong L, Liang T, Fillgrove K, et al.
ACS Med Chem Lett . 2023 Feb; 14(2):146-155. PMID: 36793422
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in GBA, the gene that encodes for...
4.
Mahoney-Crane C, Viswanathan M, Russell D, Curtiss R, Freire J, Bobba S, et al.
J Neurosci . 2023 Jan; 43(3):501-521. PMID: 36639889
The most common genetic risk factor for Parkinson's disease (PD) is heterozygous mutations , which encodes for the lysosomal enzyme, glucocerebrosidase. Reduced glucocerebrosidase activity associates with an accumulation of abnormal...
5.
Awasthi S, Spellman D, Hatcher N
Proteomes . 2022 Aug; 10(3). PMID: 35997438
Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline. The two cardinal neuropathological hallmarks of AD include the buildup of cerebral β amyloid (Aβ) plaques and...
6.
Zhang N, Hatcher N, Ekroos K, Kedia K, Kandebo M, Marcus J, et al.
J Lipid Res . 2022 Apr; 63(6):100218. PMID: 35489416
A major challenge of lipidomics is to determine and quantify the precise content of complex lipidomes to the exact lipid molecular species. Often, multiple methods are needed to achieve sufficient...
7.
Satapati S, Downes D, Metzger D, Shankaran H, Talukdar S, Zhou Y, et al.
SLAS Discov . 2022 Jan; 27(1):20-28. PMID: 35058172
Screening campaigns, especially those aimed at modulating enzyme activity, often rely on measuring substrate→product conversions. Unfortunately, the presence of endogenous substrates and/or products can limit one's ability to measure conversions....
8.
Cosden M, Jinn S, Yao L, Gretzula C, Kandebo M, Toolan D, et al.
Neurobiol Dis . 2021 Sep; 159:105507. PMID: 34509608
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph)....
9.
Rocha E, De Miranda B, Castro S, Drolet R, Hatcher N, Yao L, et al.
Neurobiol Dis . 2019 Oct; 134:104626. PMID: 31618685
LRRK2 has been implicated in endolysosomal function and likely plays a central role in idiopathic Parkinson's disease (iPD). In iPD, dopaminergic neurons within the substantia nigra are characterized by increased...
10.
Usenovic M, Niroomand S, Drolet R, Yao L, Gaspar R, Hatcher N, et al.
J Neurosci . 2015 Oct; 35(42):14234-50. PMID: 26490863
Significance Statement: Several independent studies have implicated tau protein as central to Alzheimer's disease progression and cell-to-cell pathology propagation. In this study, we investigated the ability of different tau species...